# ![@TaxiBiotech Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1340292496937644033.png) @TaxiBiotech TaxiBiotech

TaxiBiotech posts on X about data, $bmea, $kymr, kymera the most. They currently have [---] followers and [---] posts still getting attention that total [---] engagements in the last [--] hours.

### Engagements: [---] [#](/creator/twitter::1340292496937644033/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1340292496937644033/c:line/m:interactions.svg)

- [--] Week [-----] +7,585%
- [--] Month [-----] +43%
- [--] Months [------] -21%
- [--] Year [-------] +443%

### Mentions: [--] [#](/creator/twitter::1340292496937644033/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1340292496937644033/c:line/m:posts_active.svg)

- [--] Month [--] -66%
- [--] Months [---] +2.20%
- [--] Year [---] +284%

### Followers: [---] [#](/creator/twitter::1340292496937644033/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1340292496937644033/c:line/m:followers.svg)

- [--] Week [---] +0.85%
- [--] Month [---] +0.64%
- [--] Months [---] +22%
- [--] Year [---] +358%

### CreatorRank: [---------] [#](/creator/twitter::1340292496937644033/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1340292496937644033/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks)  72% [finance](/list/finance)  9% [cryptocurrencies](/list/cryptocurrencies)  4% [technology brands](/list/technology-brands)  4% [celebrities](/list/celebrities)  2% [countries](/list/countries)  1% [exchanges](/list/exchanges)  1%

**Social topic influence**
[data](/topic/data) 13%, [$bmea](/topic/$bmea) 6%, [$kymr](/topic/$kymr) 4%, [kymera](/topic/kymera) 4%, [$pfsa](/topic/$pfsa) 3%, [the first](/topic/the-first) 3%, [target](/topic/target) 3%, [$plrx](/topic/$plrx) 3%, [$lxeo](/topic/$lxeo) 3%, [$howl](/topic/$howl) 3%

**Top accounts mentioned or mentioned by**
[@at_truthmatters](/creator/undefined) [@ohwhyamerica](/creator/undefined) [@biotech2k1](/creator/undefined)

**Top assets mentioned**
[Biomea Fusion, Inc. (BMEA)](/topic/$bmea) [Kymera Therapeutics, Inc. (KYMR)](/topic/$kymr) [Pliant Therapeutics, Inc. (PLRX)](/topic/$plrx) [Lexeo Therapeutics, Inc (LXEO)](/topic/$lxeo) [Werewolf Therapeutics, Inc. (HOWL)](/topic/$howl) [Candel Therapeutics, Inc. (CADL)](/topic/$cadl) [Oric Pharmaceuticals, Inc. (ORIC)](/topic/$oric) [Pfizer, Inc. (PFE)](/topic/$pfe) [uniQure N.V. (QURE)](/topic/$qure) [Fractyl Health, Inc. (GUTS)](/topic/$guts) [ImmunityBio, Inc. Common Stock (IBRX)](/topic/$ibrx) [Upstream Bio, Inc. (UPB)](/topic/$upb) [Pyxis Oncology, Inc. (PYXS)](/topic/$pyxs) [Synthetify (SNY)](/topic/$sny) [Tenaya Therapeutics, Inc.  (TNYA)](/topic/$tnya) [Instil Bio, Inc. (TIL)](/topic/$til) [ALX Oncology Holdings Inc (ALXO)](/topic/$alxo) [Black Diamond Therapeutics Inc. (BDTX)](/topic/$bdtx) [MBX Biosciences, Inc. (MBX)](/topic/mbx-biosciences) [Marblex (MBX)](/topic/$mbx) [Pharvaris, B.V. (PHVS)](/topic/$phvs) [Mineralys Therapeutics, Inc. (MLYS)](/topic/$mlys) [Certara, Inc. (CERT)](/topic/$cert) [Relay Therapeutics, Inc. (RLAY)](/topic/$rlay) [Immuneering Corporation (IMRX)](/topic/$imrx) [Century Therapeutics, Inc. (IPSC)](/topic/$ipsc) [Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)](/topic/$amrx) [Terns Pharmaceuticals, Inc. (TERN)](/topic/$tern) [Denali Therapeutics Inc. Common Stock (DNLI)](/topic/$dnli) [Valneva SE (VALN)](/topic/$valn) [Krystal Biotech, Inc. Common Stock (KRYS)](/topic/$krys) [Madrigal Pharmaceuticals, Inc. Common Stock (MDGL)](/topic/$mdgl) [Hims & Hers Health, Inc. (HIMS)](/topic/$hims) [Boundless Bio, Inc (BOLD)](/topic/boundless-bio) [Liquity BOLD (BOLD)](/topic/$bold) [Centessa Pharmaceuticals plc (CNTA)](/topic/$cnta) [Dyne Therapeutics, Inc. (DYN)](/topic/dyne-therapeutics)
### Top Social Posts
Top posts by engagements in the last [--] hours

"11_12_25 🗞🧬 Biotech Stock News. Daily Recap. English REZOLUTE $RZLT VALNEVA $VALN IMMATICS $IMTX ACIMMUNE $ACIU CORBUS $CRBP"  
[X Link](https://x.com/TaxiBiotech/status/1999153197521248614)  2025-12-11T16:23Z [---] followers, [---] engagements


"January_09_26 🗞🧬 Biotech Stock News. Daily Recap. English $KRYS Krystal Biotech $PDSB PDS Biotechnology $MDGL Madrigal Pharmaceuticals $PFE Pfizer $QURE uniQure $AQST Aquestive Therapeutics $LNA Leona Bio (antes Athira Pharma) MapLight Therapeutics (Privada) $ASND Ascendis Pharma. https://twitter.com/i/web/status/2009685509426016715 https://twitter.com/i/web/status/2009685509426016715"  
[X Link](https://x.com/TaxiBiotech/status/2009685509426016715)  2026-01-09T17:55Z [---] followers, [---] engagements


"01_29_26 Biotech Stock News . Daily Recap. #English $APRE $IMMP $SER $GUTS $PFSA #Shorts $XBI #trading #biotechnews #dailynews https://www.youtube.com/shorts/XAWOll0heF4 https://www.youtube.com/shorts/XAWOll0heF4"  
[X Link](https://x.com/TaxiBiotech/status/2016909657571221694)  2026-01-29T16:21Z [---] followers, [---] engagements


"Biotechs are so misunderstood. They invest hundreds of millions to save lives yet the world expects drugs for free💔 $HIMS And because of patents they only have [--] years to maximize returns. After that they go FREE. How much is health worth Is it time to reform patents"  
[X Link](https://x.com/TaxiBiotech/status/2021105009287410163)  2026-02-10T06:12Z [---] followers, [---] engagements


"Es ImmunityBio $IBRX la gran revolucin o puro humo 🧬 Analizamos a fondo la ciencia detrs de Anktiva sus resultados y competencia y si su CEO es realmente el "Elon Musk" de la biotecnologa. 🚀🧪 #ImmunityBio #Bolsa #Biotech #Inversiones https://www.youtube.com/watchv=8dH4updxzLU https://www.youtube.com/watchv=8dH4updxzLU"  
[X Link](https://x.com/TaxiBiotech/status/2021246806823154143)  2026-02-10T15:36Z [---] followers, [----] engagements


"Is ImmunityBio $IBRX the next big revolution or just hype Deep diving into the science behind Anktiva its 71% CR in bladder cancer other drugs in bladder cancer and if their CEO is the "Elon Musk" of biotech. 🚀🧪 #Biotech #StockMarket #Investing https://www.youtube.com/watchv=upF8w_ptfDc https://www.youtube.com/watchv=upF8w_ptfDc"  
[X Link](https://x.com/TaxiBiotech/status/2021247456244080693)  2026-02-10T15:38Z [---] followers, [---] engagements


"$BOLD Boundless Bio Cash: $117.6 M Runway: Through mid-2028. Q3 net loss: $13.9 M vs $16.5 M in Q324. Pipeline: Enrollment ongoing in BBI-355 / BBI-825 combination. BBI-940 (Kinesin degrader) IND planned H1 [----]. Next milestone: Initiation of first-in-human trial for BBI-940 in H1 [----] 👉 https://www.globenewswire.com/news-release/2025/11/05/3181282/0/en/Boundless-Bio-Reports-Third-Quarter-2025-Financial-Results-and-Business-Highlights.html https://www.globenewswire.com/news-release/2025/11/05/3181282/0/en/Boundless-Bio-Reports-Third-Quarter-2025-Financial-Results-and-Business-Highlights.html"  
[X Link](https://x.com/TaxiBiotech/status/1986460428063371270)  2025-11-06T15:47Z [---] followers, [---] engagements


"$UPB es una oportunidad Los deberes del video de noticias de hoy: Reduccin significativa de ataques de asma. Pero la eficacia cae en las dosis a [--] semanas. Se cuestiona su ventaja competitiva frente a la competencia. Rally +300% YoY = venta por debajo de las expectativas. https://www.youtube.com/shorts/gOasQfKL4-U https://www.youtube.com/shorts/gOasQfKL4-U"  
[X Link](https://x.com/TaxiBiotech/status/2021655028399014024)  2026-02-11T18:38Z [---] followers, [---] engagements


"Is $UPB an opportunity Key takeaways from today's VIDEO news: Significant reduction in asthma attacks. However efficacy drops with 24-week dosing. Competitive advantage against peers is being questioned. +300% YoY rally = sell-off as results came in below expectations. https://www.youtube.com/shorts/T_d0rVuiHzs https://www.youtube.com/shorts/T_d0rVuiHzs"  
[X Link](https://x.com/TaxiBiotech/status/2021655695905489100)  2026-02-11T18:40Z [---] followers, [---] engagements


"This news certainly hurts investment in the industry. But analyzing just the product there's a clear hurdle for mRNA flu vaccines in EUROPE: public preference. Most people still lean toward traditional FLU shots (even at 50% efficacy) over mRNA platforms. The backlash from the COVID-19 era has created a stigma that's hard to overcome when 'good enough' alternatives exist. In my circles annual flu shots are standard but COVID boosters are not. Until this generational mindset shifts it might be wiser to target diseases that lack competent therapies rather than disrupting what already works. Is"  
[X Link](https://x.com/TaxiBiotech/status/2021819327767331259)  2026-02-12T05:31Z [---] followers, [---] engagements


"$PYXS (Pyxis Oncology) Cash: $77.7M Runway: into 2H [----]. Q3 Net loss $22M. ($21.1M in Q3 2024) Next catalysts: Preliminary MICVO (micvotabart pelidotin) Phase [--] R/M HNSCC data expected in Q425"  
[X Link](https://x.com/TaxiBiotech/status/1986097415653294208)  2025-11-05T15:44Z [---] followers, [---] engagements


"$CNTA Centessa Pharmaceuticals Cash: $349 M runway to mid-2027. net loss: $54.9M vs $42.6M Q3 [----] Pipeline: OX2R agonist program with ORX750 registrational program in Q1 [----] ORX489 to IND ORX142 initiation Q1 [----] 👉 https://www.globenewswire.com/news-release/2025/11/05/3181265/0/en/Centessa-Pharmaceuticals-Reports-Financial-Results-for-the-Third-Quarter-of-2025-and-Provides-Update-on-Potential-Best-in-Class-Orexin-Receptor-2-OX2R-Agonist-Program.html"  
[X Link](https://x.com/TaxiBiotech/status/1986460417669955631)  2025-11-06T15:47Z [---] followers, [---] engagements


"$LRMR Larimar Therapeutics Cash: $175.4M. runway into Q4 [----]. Q3 net loss: $47.7M vs $15.5M in Q324. Pipeline: Lead asset nomlabofusp (for Friedreichs ataxia) BLA submission targeted Q2 [----] U.S. launch early [----]. 👉 https://www.globenewswire.com/news-release/2025/11/05/3181277/0/en/Larimar-Therapeutics-Reports-Third-Quarter-2025-Financial-Results.html https://www.globenewswire.com/news-release/2025/11/05/3181277/0/en/Larimar-Therapeutics-Reports-Third-Quarter-2025-Financial-Results.html"  
[X Link](https://x.com/TaxiBiotech/status/1986460422992515093)  2025-11-06T15:47Z [---] followers, [---] engagements


"$AQST Aquestive Therapeutics Cash: $129.1M. Estimated cash runway and sufficiency to support the launch of Anaphylm if approved by the FDA Q325: Net loss $15.4M (vs 11.5M in Q3 2024) Next milestones: PDUFA DATE JAN [--] [----] for Anaphylm. The first and only oral medication for the rescue treatment of severe allergic reactions including anaphylaxis"  
[X Link](https://x.com/TaxiBiotech/status/1986769318525206758)  2025-11-07T12:14Z [---] followers, [---] engagements


"$DYN Dyne Therapeutics Cash: $792M Runway: into Q327 Q325: Net loss $108M (vs 97M Q3 2024) Next milestones: Topline data for DYNE-251 in DMD on track for December [----] to support potential submission for U.S. Accelerated Approval in Q2 2026"  
[X Link](https://x.com/TaxiBiotech/status/1986769320777498819)  2025-11-07T12:14Z [---] followers, [---] engagements


"$PRQR ProQR Cash: 106.9M Runway: mid-27 Q325: Net loss 11M Next milestones: Phase [--] study of AX-0810 in healthy volunteers initial safety tolerability and PK data from Cohort [--] expected by year-end. target engagement data from all cohorts in H1 2026"  
[X Link](https://x.com/TaxiBiotech/status/1986769325659914443)  2025-11-07T12:14Z [---] followers, [---] engagements


"$NEUM Neumora Therapeutics Cash: $171M Runway [----] Q325: Net loss $56.8M (vs [----] Q3 2024) Next milestones: END 2025: Data from Phase 1b study of NMRA-511 in Alzheimers disease agitation Q1 [----] highly brain-penetrant oral NLRP3 inhibitor"  
[X Link](https://x.com/TaxiBiotech/status/1986769328432107750)  2025-11-07T12:14Z [---] followers, [---] engagements


"04_12_25 Biotech Stock News. Daily Recap. English $PLRX $PSTV $QURE $CBIO $SNTI $PPCB $SNY $ENLV"  
[X Link](https://x.com/TaxiBiotech/status/1996603391019974904)  2025-12-04T15:31Z [---] followers, [---] engagements


"15_DECEMBER_25 🗞🧬 Biotech Stock News. Daily Recap. English Kyverna $KYTX Rezolute $RZLT Milestone $MIST Adaptive $ADPT Pfizer $PFE Fortress $FBIO Profusa $PFSA Dyadic $DYAI FibroGen $FGEN Sanofi $SAN Sanofi $SNY"  
[X Link](https://x.com/TaxiBiotech/status/2000590550223696151)  2025-12-15T15:35Z [---] followers, [---] engagements


"29_01_26 Noticias de acciones biotecnolgicas . Resumen diario. $APRE $IMMP $SER $GUTS $PFSA #Espaol #Shorts #diario $XBI https://www.youtube.com/shorts/rfNZi5I00GY https://www.youtube.com/shorts/rfNZi5I00GY"  
[X Link](https://x.com/TaxiBiotech/status/2016909588981768259)  2026-01-29T16:21Z [---] followers, [---] engagements


"$LXEO Lexeo Therapeutics Expresar APOE2 y contrarrestar los efectos de Alzheimer por APOE4 SeguraOK. Expresin leve de APOE2OK Pero no est claro cmo una expresin leve de APOE2 podra afectar a una enfermedad ya en progreso. El precio de la accin refleja el sentimiento"  
[X Link](https://x.com/TaxiBiotech/status/1851875876503191747)  2024-10-31T06:36Z [---] followers, [---] engagements


"$ETNB 89Bio. Ph3 ENTRUST trial in patients with severe hypertriglyceridemia (SHTG): topline 26-week data in the 2H [----] Ph3 ENLIGHTEN program in patients with metabolic dysfunction-associated steatohepatitis (MASH) continues to enroll patients"  
[X Link](https://x.com/TaxiBiotech/status/1879124291356414120)  2025-01-14T11:11Z [---] followers, [---] engagements


"$HOWL Werewolf Therapeutics. Data from expansion arms in Phase 1/1b for WTX-124 as monotherapy in 1H to potential registrational pathways +Data in combination with pembrolizumab in 4Q Initiation of Phase 1/2 for WTX-330 in Q1 Cash runway through Q2 2026"  
[X Link](https://x.com/TaxiBiotech/status/1879124293780725915)  2025-01-14T11:11Z [---] followers, [---] engagements


"$PMN ProMIS Neurosciences. PRECISE-AD Phase 1b interim data 1H [----]. Topline results end [----]. Candidates into the clinic in 12-18 months: PMN267 for misfolded TDP-43 in ALS and FTD. PMN442 for misfolded alpha-synuclein in MSA and Parkinson. Vaccine program: PMN400 for MSA Parkinson and Lewy Body Dementia. + PMN311 for AD"  
[X Link](https://x.com/TaxiBiotech/status/1879448314627690915)  2025-01-15T08:39Z [---] followers, [---] engagements


"$BMEA Biomea Fusion. Biomea will become a diabetes and obesity company. Prioritize insulin-deficient patients and GLP-1-based therapies. COVALENT-111 results at upcoming conferences. Plans to conclude icovamenibs studies in oncology and explore partnerships for the assets"  
[X Link](https://x.com/TaxiBiotech/status/1879448318985843057)  2025-01-15T08:39Z [---] followers, [---] engagements


"$KYMR Kymera. KT-621 (STAT6) Ph1 data expected in 2Q25. Initiate a KT-621 Ph1b in atopic dermatitis (AD) in 2Q25 with data in 4Q25. + initiate parallel Phase 2b trials in AD in late [----] and asthma in early [----]. KT-295 (TYK2) Phase [--] testing in 2Q25 with data 4Q25. KT-474/SAR444656 (IRAK4) Phase 2b hidradenitis suppurativa and AD ongoing completion in 1H26 and mid-2026. Novel oral immunology program with a first-in-class development candidate to be disclosed in 1H25. $850M cash and runway into mid-2027"  
[X Link](https://x.com/TaxiBiotech/status/1879448325377622341)  2025-01-15T08:39Z [---] followers, [---] engagements


"$C4T C4 Therapeutics. Cemsidomide: oral degrader of IKZF1/3 for relapsed/refractory (R/R) multiple myeloma (MM) and R/R non-Hodgkins lymphoma (NHL) Data in 2H2025. CFT1946 Ph1 BRAF V600X Solid Tumors: Data in Melanoma and Colorectal Cancer in 2H2025. $ runway 2027"  
[X Link](https://x.com/TaxiBiotech/status/1879448327437320541)  2025-01-15T08:39Z [---] followers, [---] engagements


"$EYPT EyePoint Full data for Phase [--] VERONA clinical trial of DURAVYU in DME expected in Q1 2025"  
[X Link](https://x.com/TaxiBiotech/status/1881594925680394491)  2025-01-21T06:49Z [---] followers, [---] engagements


"$HOWL Werewolf Therapeutics. Data from expansion arms in Phase 1/1b for WTX-124 as monotherapy in H1 to potential registrational pathways +Data in combination with pembrolizumab in Q4 Initiation of Phase 1/2 for WTX-330 in Q1"  
[X Link](https://x.com/TaxiBiotech/status/1881594927622336897)  2025-01-21T06:49Z [---] followers, [--] engagements


"$CADL Candel CAN-2409: Ph2 Overall survival in pancreatic (PDAC) and lung cancer (NSCLC): Q1 [----] + data of prostate cancer in upcoming scientific conferences"  
[X Link](https://x.com/TaxiBiotech/status/1881594929660694851)  2025-01-21T06:49Z [---] followers, [---] engagements


"$TNYA Tenaya therapeutics. Cohort [--] Data: MyPEAK-1 Phase 1b/2 of TN-201 for MYBPC3-cardiomyopathy HCM in H1 25"  
[X Link](https://x.com/TaxiBiotech/status/1881594931648823317)  2025-01-21T06:49Z [---] followers, [---] engagements


"Instil Bio $TIL Clinical data update for SYN-2510/IMM2510 (a PD-L1xVEGF bispecific antibody) anticipated in 1H [----] Some previous results:"  
[X Link](https://x.com/TaxiBiotech/status/1897171109944176901)  2025-03-05T06:23Z [---] followers, [---] engagements


"Instil Bio $TIL Actualizacin de datos clnicos para SYN-2510/IMM2510 (un anticuerpo biespecfico PD-L1xVEGF) para el 1H de [----]. Algunos resultados previos:"  
[X Link](https://x.com/TaxiBiotech/status/1897173029618376822)  2025-03-05T06:31Z [---] followers, [---] engagements


"Noticia de noviembre [----] ya comentaban 1H [----] https://ir.instilbio.com/news-releases/news-release-details/instil-bio-reports-third-quarter-2024-financial-results-and https://ir.instilbio.com/news-releases/news-release-details/instil-bio-reports-third-quarter-2024-financial-results-and"  
[X Link](https://x.com/TaxiBiotech/status/1897173034399866885)  2025-03-05T06:31Z [---] followers, [--] engagements


"PEPGEN $PEGN est siendo investigada en nombre de los inversores de PepGen Inc. Ya se saba que su estudio con Duchenne no iba muy bien pero mejor as se perfila an ms la idea de este video 👇 https://youtu.be/VEdhPvKA1U4 https://www.tradingview.com/news/reuters.com2025-03-13:newsml_ACSTvtmXa:0/ https://youtu.be/VEdhPvKA1U4 https://www.tradingview.com/news/reuters.com2025-03-13:newsml_ACSTvtmXa:0/"  
[X Link](https://x.com/TaxiBiotech/status/1902412429608231269)  2025-03-19T17:30Z [---] followers, [---] engagements


"$CABA Cabaletta 📣 Clinical/translational data on rese-cel at EULAR [----] (June) 💰 Cash + equivalents: $164M 🛡 Operational runway: 1H26"  
[X Link](https://x.com/TaxiBiotech/status/1907362047618081172)  2025-04-02T09:18Z [---] followers, [---] engagements


"$CADL Candel Therapeutics 🧬 presenta resultados positivos de Fase3 CAN2409 🎯 En cncer de prstata localizado. CAN-2409+prodrug + radiacin estndar 📣 Presentacin oral en ASCO [----] 📅 [--] de junio 9:4512:45h CT #ASCO25 #ProstateCancer #Biotech https://www.globenewswire.com/news-release/2025/04/23/3066873/0/en/Candel-Therapeutics-Announces-Oral-Presentation-of-Positive-Phase-3-CAN-2409-Results-in-Localized-Prostate-Cancer-at-ASCO-2025.html"  
[X Link](https://x.com/TaxiBiotech/status/1915347753699324035)  2025-04-24T10:11Z [---] followers, [---] engagements


"8/ ImmuCell Corporation ( $ICCC ) 🧪 Re-Tain: Initiated investigational product use to gather market feedback in H2 2025; exploring strategic options for this mastitis treatment. 💰 Q1 [----] revenue: $8.1M (+11% YoY) 📈 Gross margin: 42% (up from 32% in Q1 2024) 📉 Net income: $1.4M (vs. $438K loss in Q1 2024) 💵 Cash & equivalents: $4.6M"  
[X Link](https://x.com/TaxiBiotech/status/1922902401771585836)  2025-05-15T06:30Z [---] followers, [---] engagements


"9/ Jade Biosciences ( $JBIO ) 🧪 JADE101: Anti-APRIL monoclonal antibody targeting IgA nephropathy (IgAN); first-in-human trial expected in H2 [----] with interim biomarker-rich data anticipated in H1 [----]. 💰 Cash & equivalents: $49.9M as of March [--] 2025; raised an additional $205M in April [----] totaling $300M. 📉 Net loss: $38.2M in Q1 [----]. 🛣 Runway projected through [----]. https://twitter.com/i/web/status/1922902405089210611 https://twitter.com/i/web/status/1922902405089210611"  
[X Link](https://x.com/TaxiBiotech/status/1922902405089210611)  2025-05-15T06:30Z [---] followers, [---] engagements


"16/ Clearside Biomedical ( $CLSD ) 🧪 CLS-AX (axitinib injectable suspension): Positive End-of-Phase [--] meeting with FDA; Phase [--] program design aligned for wet AMD. 📉 Net loss: $3.6M 💵 Cash & equivalents: $20.1M"  
[X Link](https://x.com/TaxiBiotech/status/1922902429479153816)  2025-05-15T06:30Z [---] followers, [---] engagements


"17/ Alumis Inc. ( $ALMS ) 🧪 ESK-001 (oral TYK2 inhibitor): Phase [--] ONWARD program for moderate-to-severe plaque psoriasis underway; topline data expected in Q1 [----]. Phase 2b trial in systemic lupus erythematosus (SLE) ongoing; data anticipated in [----]. Entered collaboration with Kaken Pharmaceutical for dermatology indications in Japan receiving $20M upfront and $20M in near-term co-development payments. 🧬 A-005 (CNS-penetrant TYK2 inhibitor): Phase [--] trial in multiple sclerosis (MS) planned to initiate in H2 [----]. 📉 Net loss: $99.0M 💵 Cash & equivalents: $208.7M as of March [--] [----] 🛣"  
[X Link](https://x.com/TaxiBiotech/status/1922902432486478248)  2025-05-15T06:30Z [---] followers, [---] engagements


"2/🧬 $GRI GRI Bio iNKT modulator (GRI-0621) for IPF 🔹Biomarker Interim data Q225 Biomarker Topline Q325 🔹Net loss: $3M Cash: $8.3M 🔹Runway through Q325"  
[X Link](https://x.com/TaxiBiotech/status/1923320881108922553)  2025-05-16T10:13Z [---] followers, [---] engagements


"Lexeo Therapeutics $LXEO Cash: $152.5M Net loss (Q2): $26.1M Runway: [----] Next H225: interim clinical data of [--] patients in Ph I/II trial (HEROIC-PKP2) of LX2020 for PKP2-ACM (CARDIO)"  
[X Link](https://x.com/TaxiBiotech/status/1956286365961764985)  2025-08-15T09:26Z [---] followers, [---] engagements


"Werewolf Therapeutics $HOWL Cash: $77.6M Net loss (Q2): $18M Runway: Q426 Next: Q425: Tolerability response rate and durability data for WTX-124 (IL2+Pembro) Mono and Combo"  
[X Link](https://x.com/TaxiBiotech/status/1956286369484915104)  2025-08-15T09:26Z [---] followers, [---] engagements


"🧬 Another NASDAQ Biotech Watchlist: names with 1yr runway and H225 [---] catalysts Based on last weeks financials & business highlights Final wave of these names dropping in the next hoursAre these actually my holidays😂 Cash P&L Runway Next Milestones Dive 👇"  
[X Link](https://x.com/TaxiBiotech/status/1957392803547226289)  2025-08-18T10:43Z [---] followers, [---] engagements


"ORIC Pharmaceuticals $ORIC Cash: $327.7M (pro forma $436.4M) Net loss Q225: ($36.4M) Runway: 2H28 Next. 2H25: Ph1b data ORIC-944 and dose-opt (Q126) 2H25 ORIC-114 data for 1L EGFR exon [--] 2L EGFR exon [--] 2L+ HER2 exon [--] and 2L+ EGFR atypical data"  
[X Link](https://x.com/TaxiBiotech/status/1957392806449668210)  2025-08-18T10:43Z [---] followers, [---] engagements


"ALX Oncology $ALXO Cash: $83.5M Net Loss Q2: $25.9M Runway: Q127 Next: Q425 ASPEN-06 CD47 Gastric Cancer updated data; 1H26 ALX2004 EGFR-expressing solid tumors Ph1 safety; Q3'26 ASPEN-BREAST"  
[X Link](https://x.com/TaxiBiotech/status/1957392829619081337)  2025-08-18T10:43Z [---] followers, [---] engagements


"Cullinan $CGEM Cash: $510M Net Loss: $70.1M Runway: [----] Next: Q425 SLE Ph1/2 initial safety Zipalertinib REZILIENT1 pivotal results shared in oral presentation at ASCO [----] and in Journal of Clinical Oncology; multiple new data sets across a range of disease settings to be shared at IASLC [----] WCLC and ESMO Congress [----] Q4 [----] Clinical data for CLN-049 (FLT3xCD3 bispecific T cell engager): Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)"  
[X Link](https://x.com/TaxiBiotech/status/1957727254730932371)  2025-08-19T08:52Z [---] followers, [---] engagements


"Rapport Therapeutics $RAPP Cash: $260.4M Net Loss Q2: $26.7M Runway: YE26 Next: RAP-219 Phase 2a trial in patients with drug-resistant focal onset seizures is fully enrolled and on track for topline results in September 2025"  
[X Link](https://x.com/TaxiBiotech/status/1957727256656167260)  2025-08-19T08:52Z [---] followers, [---] engagements


"$SNDX (Syndax) Cash & investments: $456.1M Q3 Net loss: $60.7M 9M Net loss: $217.4M Pipeline/updates: Revuforj (revumenib) FDA-approved (Oct 24) in R/R NPM1m AML; strong Niktimvo (axatilimab-csfr) uptake Next catalysts: multiple ASH [----] revumenib/axatilimab presentations; IPF Ph2 axatilimab enrollment complete by YE25"  
[X Link](https://x.com/TaxiBiotech/status/1986097376793088459)  2025-11-05T15:44Z [---] followers, [---] engagements


"$MYGN (Myriad Genetics) Cash: $145.4M Q3 Net loss: $27.4M 9M Net loss: $358.0M Pipeline/updates: first AI-driven prostate cancer test (with PathomIQ) planned for 1H26; CDx collaboration with SOPHiA GENETICS Next catalysts: oncology commercial execution; progress in AI tests and EMR rollout https://twitter.com/i/web/status/1986097379221639364 https://twitter.com/i/web/status/1986097379221639364"  
[X Link](https://x.com/TaxiBiotech/status/1986097379221639364)  2025-11-05T15:44Z [---] followers, [---] engagements


"$NVCT (Nuvectis Pharma) Cash: $35.4M Runway: Expected into Q3 [----]. Q3 Net loss: $7.5M. Pipeline/updates: Initiated Phase 1b for NXP900 monotherapy; completed Phase 1a dose-escalation with robust pharmacodynamics; DDI study done. Stock Titan Next catalysts: Early Phase 1b monotherapy readouts; combination dosing initiation by year-end. https://twitter.com/i/web/status/1986097404693631352 https://twitter.com/i/web/status/1986097404693631352"  
[X Link](https://x.com/TaxiBiotech/status/1986097404693631352)  2025-11-05T15:44Z [---] followers, [---] engagements


"$DCTH (Delcath Systems) Cash : $88.9 million Q3 Net income : $0.8 million (vs. $1.9 million income in Q3 2024) Revenue: $20.6 million in Q3 [----] vs. $11.2 million in Q3 [----] (+84%) Pipeline/updates: First patient dosed in global Phase [--] HEPZATO KIT combo trial for liver-dominant mCRC; investigator-initiated Phase [--] CHOPIN trial in metastatic uveal melanoma presented improved 1-yr PFS. Next catalysts: Top-line data expected [----] from the Phase [--] HEPZATO combo trial; expansion of treatment centers; commercialization scaling of HEPZATO & CHEMOSAT"  
[X Link](https://x.com/TaxiBiotech/status/1986097421198221668)  2025-11-05T15:44Z [---] followers, [---] engagements


"$HRMY (Harmony Biosciences) Cash: $778M Net income: $50.9M (vs $46.1M Q3 2024) Pipeline/updates: Submitted IND for pitolisant HD; initiating Phase [--] in narcolepsy & idiopathic hypersomnia in Q4 2025; potential best-in-class orexin-2 agonist (BP1.15205) to dose first subject in Q4 [----] and Phase [--] Clinical Data in 2026; multiple Phase [--] programs (up to five) by year-end. https://twitter.com/i/web/status/1986097423840584004 https://twitter.com/i/web/status/1986097423840584004"  
[X Link](https://x.com/TaxiBiotech/status/1986097423840584004)  2025-11-05T15:45Z [---] followers, [---] engagements


"$MLTX MoonLake Immunotherapeutics Cash/runway: $380M. Runway H2 [----] Net loss: $70M. Pipeline: Confirmed a Type B meeting with the FDA on December [--] [----] to support a BLA of SLK in HS. Other clinical trials of SLK expected data releases from the Phase [--] S-OLARIS trial in Axial Spondyloarthritis (axSpA) and the Phase [--] IZAR trials in Psoriatic Arthritis (PsA) 👉 https://www.globenewswire.com/news-release/2025/11/05/3181261/0/en/MoonLake-Immunotherapeutics-Reports-Third-Quarter-2025-Financial-Results-and-Announces-New-Data-from-Clinical-Trials-of-its-Nanobody-Sonelokimab.html"  
[X Link](https://x.com/TaxiBiotech/status/1986460412426998136)  2025-11-06T15:47Z [---] followers, [---] engagements


"$UPST Upstream Bio Cash: $372M. Runway [----]. - Net loss: $33.7M vs $16M in [----]. Pipeline: On-track to report top-line results from VALIANT Phase [--] trial in severe asthma in the first quarter of [----] 👉 https://www.globenewswire.com/news-release/2025/11/05/3181264/0/en/Upstream-Bio-Reports-Third-Quarter-2025-Financial-Results-and-Highlights-Continued-Progress.html https://www.globenewswire.com/news-release/2025/11/05/3181264/0/en/Upstream-Bio-Reports-Third-Quarter-2025-Financial-Results-and-Highlights-Continued-Progress.html"  
[X Link](https://x.com/TaxiBiotech/status/1986460414633193698)  2025-11-06T15:47Z [---] followers, [---] engagements


"$SION Sionna Therapeutics Cash: $325.0M runway into [----]. Q3 net loss: $20.3M vs $25.4M in Q324. Pipeline: Initiated Phase 2a proof-of-concept trial of SION-719 (NBD1 stabilizer) in CF as add-on to standard of care; also initiated Phase [--] trial of SION-451 in dual combinations. Next milestone: Topline data from both trials expected mid-2026. 👉 https://www.globenewswire.com/news-release/2025/11/05/3181269/0/en/Sionna-Therapeutics-Reports-Third-Quarter-2025-Financial-Results.html https://twitter.com/i/web/status/1986460420853338476"  
[X Link](https://x.com/TaxiBiotech/status/1986460420853338476)  2025-11-06T15:47Z [---] followers, [--] engagements


"$FHTX Foghorn Therapeutics Cash: $180.3 M Runway: Into [----]. Q3 net loss: $15.8 M vs $19.1 M in Q324. Pipeline: FHD-909 (SMARCA2 inhibitor) in Phase 1; collaborating with Eli Lilly and Company on degraders (CBP EP300 ARID1B) in oncology. Next milestone: IND-readiness for select CBP degrader in 2026; in vivo PoC for ARID1B degrader in [----]. 👉 https://www.globenewswire.com/news-release/2025/11/05/3181279/0/en/Foghorn-Therapeutics-Provides-Third-Quarter-2025-Financial-and-Corporate-Update.html"  
[X Link](https://x.com/TaxiBiotech/status/1986460425525850341)  2025-11-06T15:47Z [---] followers, [---] engagements


"$BDTX Black Diamond Therapeutics Cash: $135.5M Runway: into Q4-2027 Q325: Net loss $8.5M (vs $15.6M Q3 2024) Next milestones: ORR and preliminary duration of treatment data for the Phase [--] trial of silevertinib in 1L patients with non-classical EGFRm NSCLC on track for this quarter. + FDA feedback on a potential registrational path in frontline EGFR mutant NSCLC in the first half of 2026"  
[X Link](https://x.com/TaxiBiotech/status/1986769343519105453)  2025-11-07T12:14Z [---] followers, [---] engagements


"$MBX MBX Biosciences Cash: $391M Runway : [----] Q325: Net loss $21M (vs $18M) Next milestones: CanvuparatideQ1 2026: End of Phase [--] meeting and EMA Scientific Advice Q2 2026: Presentation of Phase [--] results at a medical meeting Q2 2026: Phase [--] one-year open label extension study data Q3 2026: Phase [--] canvuparatide HP trial initiation MBX 4291Q4 2026: Results from 12-week multiple ascending dose portion of Phase [--] trial of MBX [----] for the treatment of obesity ImapextideQ2 2026: Phase 2a STEADI trial results of imapextide for the treatment of post-bariatric hypoglycemia (PBH)"  
[X Link](https://x.com/TaxiBiotech/status/1986769346014634199)  2025-11-07T12:14Z [---] followers, [---] engagements


"🧬 ALX Oncology ( $ALXO ) Cash: $66.5M. Runway: Q1 [----]. Net loss Q3: $22.1M (vs $30.7 2024) Business highlights & pipeline: ASPEN-06 data: lead drug evorpacept (CD47 blocker) showed durable benefit in HER2+ gastric cancer with high CD47 expression. Phase [--] ASPEN-09 (breast cancer) on track for first-patient in Q4 2025; interim data expected Q3 [----]. ALX2004 (EGFR-targeted ADC) Phase [--] initiated initial safety data due H1 [----]. https://twitter.com/i/web/status/1987412211464122400 https://twitter.com/i/web/status/1987412211464122400"  
[X Link](https://x.com/TaxiBiotech/status/1987412211464122400)  2025-11-09T06:49Z [---] followers, [---] engagements


"03_12_25 Biotech Stock News. Daily Recap. English $CAPR $PHVS $BCRX $OKYO $BDTX $RLMD $CLNN $BNTX $CVAC"  
[X Link](https://x.com/TaxiBiotech/status/1996276797369921788)  2025-12-03T17:54Z [---] followers, [---] engagements


"$TNYA Tenaya therapeutics. Cohort [--] Data: MyPEAK-1 Phase 1b/2 of TN-201 for MYBPC3-cardiomyopathy HCM in 1H25. Initial data: RIDGE-1 Phase 1b of TN-401 for PKP2 Arrhythmogenic Right Ventricular Cardiomyopathy in 2H25"  
[X Link](https://x.com/TaxiBiotech/status/1879448316720844859)  2025-01-15T08:39Z [---] followers, [---] engagements


"$AKRO Akero Therapeutics. $300M public offering + $45M option. Funds will support Phase [--] trials of its MASH treatment $300M oferta pblica de acciones + opcin de $45M. Los fondos impulsarn fase [--] de su tratamiento para MASH. https://ir.akerotx.com/news-releases/news-release-details/akero-therapeutics-announces-proposed-public-offering-common-2 https://ir.akerotx.com/news-releases/news-release-details/akero-therapeutics-announces-proposed-public-offering-common-2"  
[X Link](https://x.com/TaxiBiotech/status/1884126149703524538)  2025-01-28T06:27Z [---] followers, [--] engagements


"$MLYS Mineralys Therapeutics Publica resultados Fase [--] del Advance-HTN en NEJM 📉 Lorundrostat [--] mg: Reduccin absoluta presin arterial: [---] mmHg Reduccin ajustada vs placebo: [--] mmHg (p=0001) 🎯 Eficaz en hipertensin resistente #Hipertensin #NEJM #Biotech https://twitter.com/i/web/status/1915348869711282552 https://www.nejm.org/doi/full/10.1056/NEJMoa2501440 https://twitter.com/i/web/status/1915348869711282552 https://www.nejm.org/doi/full/10.1056/NEJMoa2501440"  
[X Link](https://x.com/TaxiBiotech/status/1915348869711282552)  2025-04-24T10:15Z [---] followers, [---] engagements


"🧬💸 Biotech al da Resultados financieros & updates (Mayo 2025) 🔹 $ANAB: Fase [--] (rosnilimab / CU) datos Q425. Caja hasta [----]. Recompra $75M 🔹 $CERT: +$4.7M neto (vs -$4.7M en Q124) 🔹 $RLAY: Fase [--] arranca mid-2025. Caja $710M ➜ runway [----] 🔹 $IMRX: Datos cncer pncreas Q225. Runway [----] 🔹 $ORIC: [--] publicaciones datos ensayos clnicos en [--] meses. $224M ➜ hasta [----] 🔹 $BMEA: Recorte de plantilla 35%. Datos 52semanas (DM2) en 2S25 🔹 $SNDX: sNDA revumenib (AML). $602M ➜ posible rentabilidad de la empresa #Biotec #Inversin #HealthTech"  
[X Link](https://x.com/TaxiBiotech/status/1919673364576153650)  2025-05-06T08:39Z [---] followers, [---] engagements


"🧬💸 Biotech Update Results & Highlights (May 2025) 🔹 $ANAB: Phase [--] (rosnilimab / UC) data in Q425. Cash runway thru [----]. $75M buyback 🔹 $CERT: +$4.7M net (vs -$4.7M in Q124) 🔹 $RLAY: Phase [--] starts mid-2025. $710M cash ➜ runway to [----] 🔹 $IMRX: Pancreatic cancer data Q225. Runway to [----] 🔹 $ORIC: [--] readouts in [--] months. $224M ➜ into [----] 🔹 $BMEA: 35% layoff. 52w data (T2D) in H225 🔹 $SNDX: sNDA for revumenib (AML). $602M ➜ to profitability #Biotech #Investing #HealthTech"  
[X Link](https://x.com/TaxiBiotech/status/1919673712447463929)  2025-05-06T08:40Z [---] followers, [---] engagements


"8/ $CKPT (Checkpoint Therapeutics) UNLOXCYT (cosibelimab-ipdl) approved by U.S. FDA in December [----] as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma. Entered into a Merger Agreement with Sun Pharmaceutical Industries Inc.; special meeting of stockholders to vote on the Merger scheduled for May [--] [----]. Q1 net loss: $11.2M. Cash & equivalents: $33.0M as of March [--] 2025"  
[X Link](https://x.com/TaxiBiotech/status/1922604780343435298)  2025-05-14T10:47Z [---] followers, [---] engagements


"9/ $CAMP (CAMP4 Therapeutics) Phase [--] clinical trial of CMP-CPS-001 for Urea Cycle Disorders (UCDs) is ongoing with dosing completed in multiple ascending dose (MAD) cohort [--]. Safety pharmacokinetic and pharmacodynamic data are expected in Q4 [----]. Nominated development candidate CMP-SYNGAP-01 to address SYNGAP1-related disorders; GLP toxicology studies expected to initiate in [----]. Achieved a milestone under the license agreement with Fulcrum Therapeutics making CAMP4 eligible to receive a $0.6 million payment. Q1 net loss: $12.4 million. - Cash $49.3M."  
[X Link](https://x.com/TaxiBiotech/status/1922604782906195987)  2025-05-14T10:47Z [---] followers, [---] engagements


"20/ $PHVS (Pharvaris N.V.) Enrollment underway in CHAPTER-3 a pivotal Phase [--] study of deucrictibant extended-release tablet for prophylaxis of hereditary angioedema (HAE) attacks; topline data expected in 2H [----]. RAPIDe-3 a pivotal Phase [--] study of deucrictibant immediate-release capsule for on-demand treatment of HAE attacks reached target enrollment in March 2025; data collection ongoing. FDA granted TQT study waivers for both deucrictibant formulations supporting their safety profiles. Q1 [----] net loss: [----] million Cash and cash equivalents: [---] million as of March [--] 2025"  
[X Link](https://x.com/TaxiBiotech/status/1922604808298541116)  2025-05-14T10:48Z [---] followers, [---] engagements


"21/ $LYEL (Lyell Immunopharma Inc.) Received RMAT designation from the FDA for LYL314 a dual-targeting CD19/CD20 CAR T-cell therapy for relapsed/refractory large B-cell lymphoma (LBCL). New clinical data from the Phase 1/2 trial of LYL314 to be presented at the 18th International Conference on Malignant Lymphoma (ICML) in June [----]. Pivotal trial in the third- or later-line setting expected to initiate mid-2025; second-line setting trial anticipated by early [----]. Q1 [----] net loss: $52.2 million. Cash cash equivalents and marketable securities: $330.1 million as of March [--] 2025; sufficient"  
[X Link](https://x.com/TaxiBiotech/status/1922604810290778384)  2025-05-14T10:48Z [---] followers, [---] engagements


"18/ Aardvark Therapeutics ( $AARD ) 🧪 ARD-101: Phase [--] HERO trial underway for hyperphagia associated with Prader-Willi Syndrome (PWS); data readout expected in early [----]. 💰 Cash & equivalents: $151.3M as of March [--] [----] (includes net proceeds from $97.9M IPO in February 2025). 📉 Net loss: $9.3M in Q1 [----]. 🛣 Runway projected into [----]. https://twitter.com/i/web/status/1922902435778941257 https://twitter.com/i/web/status/1922902435778941257"  
[X Link](https://x.com/TaxiBiotech/status/1922902435778941257)  2025-05-15T06:30Z [---] followers, [--] engagements


"19/ Oruka Therapeutics ( $ORKA ) 🧪 ORKA-001 (IL-23p19 mAb): Phase [--] trial dosing completed in [--] healthy volunteers; interim PK data expected in Q3 [----]. Phase 2a in moderate-to-severe plaque psoriasis to initiate in H2 [----] targeting PASI [---] at week [--] with extended dosing intervals (6 months or longer). Preclinical data suggest a half-life over [--] days in NHPs supporting potential for once or twice-yearly dosing. 🧬 ORKA-002 (IL-17A/F mAb): Phase [--] trial initiation advanced to Q2 2025; interim PK data anticipated around year-end [----]. 💰 Cash & equivalents: $373M as of March [--] [----] 📉"  
[X Link](https://x.com/TaxiBiotech/status/1922902439566475455)  2025-05-15T06:30Z [---] followers, [---] engagements


"6/ 🧬 $IPSC Century Therapeutics iPSC-based allogeneic cell therapies 🔹CNTY-101: dosing underway 🔹CNTY-308 IND-enabling mid-2025 🔹Q1 net income: $76.6M 🔹Cash: $185.8M Runway into Q426"  
[X Link](https://x.com/TaxiBiotech/status/1923320888692289641)  2025-05-16T10:13Z [---] followers, [---] engagements


"💊 Is the obesity drug race overcrowded 👉 Zealand Pharma ( $ZEAL ): dapiglutide (GLP1/GLP2) showed 11.6% weight loss in [--] weeks well tolerated few GI events [--] dropouts due to nausea/vomiting. 👉 Biomea Fusion ( $BMEA ): oral GLP1 agonist with strong weight loss in preclinical models. 🔑 What will truly set these drugs apart: ✔ Fewer GI side effects ✔ Oral delivery potential ✔ And above all LESS MUSCLE LOSS #biotech #obesity #GLP1 #GLP2 https://twitter.com/i/web/status/1935600134072463642 https://twitter.com/i/web/status/1935600134072463642"  
[X Link](https://x.com/TaxiBiotech/status/1935600134072463642)  2025-06-19T07:26Z [---] followers, [---] engagements


"💊 La carrera por las molculas contra la obesidad est saturada: 👉 Zealand Pharma $ZEAL : dapiglutide (GLP1/GLP2) muestra [---] % de peso en [--] semanas buena tolerabilidad pocos eventos GI [--] retiros por nuseas/vmitos. 👉 Biomea Fusion $BMEA : agonista oral GLP1 con fuerte prdida de peso en modelos preclnicos. 🔑 Lo que marcar la diferencia en estos frmacos para la obesidad: ✔ Menos nuseas y vmitos ✔ posibilidad oral ✔ Y sobre todo PERDER MENOS MSCULO #biotech #obesidad #GLP1 #GLP2 https://twitter.com/i/web/status/1935601103933952341 https://twitter.com/i/web/status/1935601103933952341"  
[X Link](https://x.com/TaxiBiotech/status/1935601103933952341)  2025-06-19T07:30Z [---] followers, [---] engagements


"$CCCC C4 Therapeutics: +7% Today💥 $100M market cap $200M in cash. They just achieved full remission in a myeloma patient. FDA talks could start soon is this stock undervalued $CCCC Analysis & other degraders here https://youtu.be/mbLqdIoAbGU https://youtu.be/mbLqdIoAbGU"  
[X Link](https://x.com/TaxiBiotech/status/1937540718702051366)  2025-06-24T15:57Z [---] followers, [----] engagements


"Kymera Therapeutics $KYMR anuncia oferta pblica de $250.8 M (5M acciones + 655K warrants) con opcin a 855K acciones adicionales 💵 Precio por accin: $44.00 📅 Cierre previsto: [--] de junio [----] 📌 Acciones en circulacin: 65M. (Diluidas totales estimadas 80M) 🎯 Objetivo: financiar su pipeline de degradadores orales para enfermedades inmunolgicas https://investors.kymeratx.com/static-files/427c6fbb-fa43-4150-9e28-e3d55b81617f https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-announces-pricing-250-million-public"  
[X Link](https://x.com/TaxiBiotech/status/1938468113034711290)  2025-06-27T05:23Z [---] followers, [---] engagements


"$PROK ProKidney resultados preliminares de Fase [--] REGEN007: 🏥 Grupo 1: la funcin renal estabilizada (2 dosis [--] en cada rin): +78 % de mejora en la pendiente anual de eGFR (de [--] antes de la inyeccin a [--] mL/min/173m tras la inyeccin p0001). 💉 Grupo [--] (1 inyeccin + segunda solo si empeora la funcin): +50 % de mejora pero sin significacin estadstica (p=0085); sugiere tendencia a respuesta por dosis. ✅ No se registraron efectos adversos graves relacionados con rilparencel. 🔜 Reunin FDA Tipo B este verano para confirmar el enfoque de PROK para Fase [--] PROACT1 con objetivo de aprobacin"  
[X Link](https://x.com/TaxiBiotech/status/1942842593399763264)  2025-07-09T07:05Z [---] followers, [---] engagements


"$PROK PROKIDNEY & FDA alignment on accelerated approval for rilparencel: ✅ FDA confirms eGFR slope is an acceptable surrogate endpoint in CKD + T2D 🧪 Ongoing Ph3 PROACT [--] for both accelerated and full approval [--] % of patients enrolled 📊 Data expected in Q2 [----] to support BLA #Biotech #FDA #CKD https://investors.prokidney.com/news-releases/news-release-details/prokidney-announces-alignment-fda-accelerated-approval-pathway https://investors.prokidney.com/news-releases/news-release-details/prokidney-announces-alignment-fda-accelerated-approval-pathway"  
[X Link](https://x.com/TaxiBiotech/status/1945135060828541193)  2025-07-15T14:55Z [---] followers, [---] engagements


"Pyxis Oncology $PYXS Cash: $90.4M Net loss Q2 $18.4M Runway: 2H26 Milestones: Ph1 monotherapy expansion of micvotabart pelidotin (MICVO) for metastatic head and neck squamous cell carcinoma (R/M HNSCC) preliminary data in H2'2025 - H1'2026 Ph1/2 MICVO + KEYTRUDA preliminary data in H2' [----] https://twitter.com/i/web/status/1956286357287977395 https://twitter.com/i/web/status/1956286357287977395"  
[X Link](https://x.com/TaxiBiotech/status/1956286357287977395)  2025-08-15T09:26Z [---] followers, [---] engagements


"Century Therapeutics $IPSC Cash: $158.5M Net loss (Q2): $32.5M Runway: Q427 Next: YE25 data updates for CNTY-101 (B-cell-mediated autoimmune diseases)"  
[X Link](https://x.com/TaxiBiotech/status/1956286360412627073)  2025-08-15T09:26Z [---] followers, [---] engagements


"Candel Therapeutics $CADL Cash: $100.7M Net loss (Q2): $4.8M Runway: Q127 Next: Q425: CAN-3110 rHGG clinical and biomarker activity data; Q426: planned BLA for CAN-2409 (prostate)"  
[X Link](https://x.com/TaxiBiotech/status/1956286385154830453)  2025-08-15T09:26Z [---] followers, [--] engagements


"Mineralys Therapeutics $MLYS Cash: $324.9M Net loss Q2: $43.3M Runway: [----] Next: Q425 pre-NDA for lorundrostat; H126 Ph2 safety & afficacy data for obstructive sleep apnea (OSA) with lorundrostat"  
[X Link](https://x.com/TaxiBiotech/status/1957392810195218704)  2025-08-18T10:43Z [---] followers, [---] engagements


"ProKidney $PROK Cash: $294.7M Net Loss Q2: $37M Runway: mid-2027 Next: Nov [--] REGEN-007 FULL RESULTS at ASN. FDA Alignment Achieved. confirmed that the slope of estimated glomerular filtration rate (eGFR) in patients from the ongoing Phase [--] PROACT [--] study can serve as the surrogate endpoint and primary basis for a Biologics License Application (BLA) submission of rilparencel under the accelerated approval pathway. Topline data readout of eGFR slope as the surrogate endpoint to support an application for accelerated approval in Q2 [----] https://twitter.com/i/web/status/1957392833205211362"  
[X Link](https://x.com/TaxiBiotech/status/1957392833205211362)  2025-08-18T10:43Z [---] followers, [---] engagements


"MBX Biosciences $MBX Cash: $224.9M Net Loss: $19.4M Runway: mid-2027 Next: Topline results for the Phase [--] Avail trial of canvuparatide in hypoparathyroidism on track for Q3 [----] Imapextide (MBX 1416) Phase 2a trial initiation in patients with post-bariatric hypoglycemia anticipated in Q3 [----] MBX [----] Phase [--] trial initiation in obesity anticipated in Q3 [----] https://twitter.com/i/web/status/1957727244870095332 https://twitter.com/i/web/status/1957727244870095332"  
[X Link](https://x.com/TaxiBiotech/status/1957727244870095332)  2025-08-19T08:52Z [---] followers, [---] engagements


"Ionis ( $IONS ) Positive topline Phase [--] results for olezarsen in severe hypertriglyceridemia and for zilganersen in Alexander disease. Regulatory filings planned in the coming months. Positive donidalorsen data in HAE & FCS multiple Phase [--] readouts in [----]. Q3 Revenue $157 M (vs 134M Q3 2024). Net loss Q3 $129M (vs $140 M a year ago). Cash $2.2 B to achieve cash flow breakeven in [----] https://www.businesswire.com/news/home/20251029676166/en/Ionis-reports-third-quarter-2025-financial-results-and-highlights-progress-on-key-programs"  
[X Link](https://x.com/TaxiBiotech/status/1983939314070233586)  2025-10-30T16:49Z [---] followers, [---] engagements


"$OCUL (Ocular Therapeutix) Cash: $344.8M Q3 Net loss: $69.4M Pipeline/updates: Positioning their implant AXPAXLI for retina market; SOL-R trial achieved target randomization of [---] subjects. Next catalysts: Updates on AXPAXLI in retina / wet AMD topline data on track for SOL-1 in 1Q [----] and SOL-R in 1H [----]. https://twitter.com/i/web/status/1986097398850945488 https://twitter.com/i/web/status/1986097398850945488"  
[X Link](https://x.com/TaxiBiotech/status/1986097398850945488)  2025-11-05T15:44Z [---] followers, [---] engagements


"$BVS (Bioventus) Cash: $30.1M Q3 Revenue: $138.7M Q3 Net income: $3.2M Pipeline/updates: Solid growth in key product portfolio focus on Platelet-Rich Plasma and nerve stimulation therapies. Next catalysts: Maintain full-year guidance margin expansion and global rollout of new therapies. https://twitter.com/i/web/status/1986097401736609808 https://twitter.com/i/web/status/1986097401736609808"  
[X Link](https://x.com/TaxiBiotech/status/1986097401736609808)  2025-11-05T15:44Z [---] followers, [---] engagements


"$BMEA Biomea Fusion Cash: $47.0M. Runway Q1 [----] Q3 net: -$16.4M vs -$32.8M [----] Next milestones: Icovamenib (menin) Ph2 start Q425 (trial COVALENT-212)and Q1 2026(trial COVALENT-211). BMF-650 wt-loss Ph1 28d data 1H26"  
[X Link](https://x.com/TaxiBiotech/status/1986460382349893704)  2025-11-06T15:47Z [---] followers, [---] engagements


"$CRVS Corvus Pharmaceuticals Cash: $65.7M Q3 net loss: $10.2M vs $40.2M (Q324) Pipeline Milestones: Lead asset Soquelitinib (ITK inhibitor) for atopic dermatitis (Phase [--] extension cohort [--] completed; data expected Jan 2026) & Phase [--] AD trial on track early Q1 [----]. Phase [--] registrational in relapsed/refractory PTCL enrolling. https://www.globenewswire.com/news-release/2025/11/04/3180825/0/en/Corvus-Pharmaceuticals-Provides-Business-Update-and-Reports-Third-Quarter-2025-Financial-Results.html"  
[X Link](https://x.com/TaxiBiotech/status/1986460394945126793)  2025-11-06T15:47Z [---] followers, [---] engagements


"$SLNO Soleno Therapeutics Cash: $556.1 M Q3 net income: +$26.0 M vs -$76.6M Q3 [----] Pipeline/Commercial: Launched VYKAT XR in the US; Q3 product revenue $66 M. Next milestone: Continued rampup of VYKAT XR; expansion into Europe and further commercial data. 👉 https://www.globenewswire.com/news-release/2025/11/04/3180820/0/en/Soleno-Therapeutics-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Update-on-U-S-Launch-of-VYKAT-TM-XR.htmlUpdate.html"  
[X Link](https://x.com/TaxiBiotech/status/1986460397423952358)  2025-11-06T15:47Z [---] followers, [---] engagements


"$ARVN Arvinas Cash: $787M Runway: Extended to H2 [----] Q3 net loss: $35.1 M vs $49.2M Q3 [----] Pipeline: partnership with Pfizer Inc. for vepdegestrant. Next milestones: Phase 1b start for ARV-102 in H1 [----]. Vepdegestrant PDUFA action date of June [--] [----]. ARV-806: Share initial clinical data in patients with solid tumors harboring KRAS G12D mutations (2026). 👉 https://www.globenewswire.com/news-release/2025/11/05/3181298/0/en/Arvinas-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.html"  
[X Link](https://x.com/TaxiBiotech/status/1986460431154618788)  2025-11-06T15:47Z [---] followers, [---] engagements


"$LXEO Lexeo Therapeutics Cash: $122.8 M +155M from stock offering Runway: expected to fund operations into [----]. Q3 net loss: $20.3 M vs $29.5 M a year ago. Pipeline: Gene therapy LX2006 in Friedreichs ataxia cardiomyopathy: interim data show 18% LVMI improvement at [--] mo 23% at [--] mo in small n=6; company advancing toward registrational study. Next milestone: LX2006 for a BLA LX2020 HEROIC-PKP2 Phase I/II trial interim data from low-dose cohort reported and additional clinical data from high-dose cohorts on track for January [----] 👉"  
[X Link](https://x.com/TaxiBiotech/status/1986460433650180571)  2025-11-06T15:47Z [---] followers, [---] engagements


"$NAMS NewAmsterdam Pharma Cash: $756.0 M cash Q3 net loss: $72.0M for Q325 vs $16.6M in Q324. Pipeline: The RUBENS trial (obicetrapib in combination with ezetimibe in patients with type [--] diabetes) is expected to initiate in the fourth quarter of [----]. 👉 https://www.globenewswire.com/news-release/2025/11/05/3181391/0/en/NewAmsterdam-Pharma-Provides-Corporate-Update-and-Reports-Third-Quarter-Financial-Results.html https://www.globenewswire.com/news-release/2025/11/05/3181391/0/en/NewAmsterdam-Pharma-Provides-Corporate-Update-and-Reports-Third-Quarter-Financial-Results.html"  
[X Link](https://x.com/TaxiBiotech/status/1986460436837900525)  2025-11-06T15:47Z [---] followers, [---] engagements


"🧪 CytomX Therapeutics ( $CTMX ) Cash: $143.6M. Runway: Q2 [----]. Net loss Q3: $14.0M (vs $+5M in Q3 2024). Lead candidate CX-2051 (EpCAM-directed topo-1 ADC) Phase [--] update expected Q1 [----]. Combination of CX-2051 with bevacizumab start in Q1 [----]. CX-801 (PROBODY interferon alpha-2b) biomarker monotherapy data to be presented at SITC [----]. https://www.globenewswire.com/news-release/2025/11/06/3183162/37704/en/CytomX-Therapeutics-Announces-Third-Quarter-2025-Financial-Results-and-Provides-Business-Update.html"  
[X Link](https://x.com/TaxiBiotech/status/1987412209526288706)  2025-11-09T06:49Z [---] followers, [---] engagements


"10_12_25 Biotech Stock News. Daily Recap. English $SAGE $AMRX $FULC $KYMR $TERN $DNLI Sagimet Amneal Fulcrum Kymera Terns Denali"  
[X Link](https://x.com/TaxiBiotech/status/1998773534634434638)  2025-12-10T15:15Z [---] followers, [---] engagements


"10_12_25 Noticias de acciones biotecnolgicas. Resumen diario. #Espaol #Shorts #Biotech $AMRX $FULC $KYMR $TERN $DNLI Sagimet Amneal Fulcrum Kymera Terns Denali"  
[X Link](https://x.com/TaxiBiotech/status/1998773555798925312)  2025-12-10T15:15Z [---] followers, [---] engagements


"🔮Hagamos un ejercicio de bola de cristal A Biotec no le sienta bien anunciar datos a [---] aos vista📉. $PLRX datos 1/2 [----] Los datos clnicos a corto plazo impulsan el precio🚀. $Atea datos Q4 [--] 👀 Sigo las aperturas. Aprendiendo. (solo entretenimiento. No inversin)"  
[X Link](https://x.com/TaxiBiotech/status/1854832897498222799)  2024-11-08T10:26Z [---] followers, [---] engagements


"🔮 Let's do a crystal ball exercise (just for fun no stocks positions here) IMO: Biotech doesnt fare well when announcing data [---] years in advance📉. $PLRX data mid-2026 Near-term announcements boost momentum🚀. $Atea data Q4 [--] 👀tracking openings. keep learning"  
[X Link](https://x.com/TaxiBiotech/status/1854833381583777798)  2024-11-08T10:28Z [---] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing